Candriam SCA’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $102M | Buy |
228,915
+3,623
| +2% | +$1.69M | 0.53% | 36 |
|
|
2025
Q4 | $102M | Buy |
225,292
+50,725
| +29% | +$21.9M | 0.51% | 38 |
|
|
2025
Q3 | $68.4M | Sell |
174,567
-1,831
| -1% | -$765K | 0.36% | 68 |
|
|
2025
Q2 | $78.5M | Sell |
176,398
-21,889
| -11% | -$10.1M | 0.45% | 46 |
|
|
2025
Q1 | $96.1M | Sell |
198,287
-60,335
| -23% | -$28.1M | 0.6% | 29 |
|
|
2024
Q4 | $104M | Sell |
258,622
-52,685
| -17% | -$24.4M | 0.6% | 29 |
|
|
2024
Q3 | $145M | Sell |
311,307
-16,964
| -5% | -$8.15M | 0.83% | 22 |
|
|
2024
Q2 | $154M | Sell |
328,271
-60,317
| -16% | -$26.2M | 0.93% | 17 |
|
|
2024
Q1 | $162M | Buy |
388,588
+46,502
| +14% | +$19.7M | 1.04% | 17 |
|
|
2023
Q4 | $139M | Sell |
342,086
-42,245
| -11% | -$15.6M | 0.96% | 18 |
|
|
2023
Q3 | $134M | Sell |
384,331
-12,231
| -3% | -$4.28M | 0.95% | 16 |
|
|
2023
Q2 | $140M | Buy |
396,562
+5,654
| +1% | +$1.91M | 1.01% | 15 |
|
|
2023
Q1 | $113M | Sell |
390,908
-78,237
| -17% | -$23.5M | 0.79% | 19 |
|
|
2022
Q4 | $135M | Sell |
469,145
-15,394
| -3% | -$4.69M | 0.91% | 15 |
|
|
2022
Q3 | $140M | Buy |
484,539
+16,656
| +4% | +$4.79M | 0.99% | 14 |
|
|
2022
Q2 | $132M | Sell |
467,883
-6,370
| -1% | -$1.7M | 1.09% | 13 |
|
|
2022
Q1 | $124M | Sell |
474,253
-170,379
| -26% | -$40.4M | 0.84% | 22 |
|
|
2021
Q4 | $142M | Buy |
644,632
+51,803
| +9% | +$10.1M | 0.9% | 18 |
|
|
2021
Q3 | $108M | Sell |
592,829
-215,038
| -27% | -$42M | 0.73% | 23 |
|
|
2021
Q2 | $163M | Buy |
807,867
+28,321
| +4% | +$5.92M | 1.12% | 10 |
|
|
2021
Q1 | $177M | Buy |
779,546
+7
| +0% | +$1.54K | 1.47% | 7 |
|
|
2020
Q4 | $184M | Buy |
779,539
+221,408
| +40% | +$50.8M | 1.46% | 7 |
|
|
2020
Q3 | $152M | Buy |
558,131
+11,940
| +2% | +$3.29M | 1.43% | 10 |
|
|
2020
Q2 | $159M | Sell |
546,191
-179,170
| -25% | -$48.6M | 1.67% | 6 |
|
|
2020
Q1 | $155M | Hold |
725,361
| – | – | 1.72% | 7 |
|
|
2019
Q4 | $159M | Sell |
725,361
-205,638
| -22% | -$41.6M | 1.7% | 7 |
|
|
2019
Q3 | $158M | Sell |
930,999
-9,507
| -1% | -$1.68M | 2.09% | 3 |
|
|
2019
Q2 | $172M | Buy |
940,506
+278,986
| +42% | +$48.8M | 2.14% | 3 |
|
|
2019
Q1 | $122M | Buy |
661,520
+26,135
| +4% | +$4.83M | 1.56% | 11 |
|
|
2018
Q4 | $105M | Buy |
635,385
+177,234
| +39% | +$30.7M | 1.62% | 8 |
|
|
2018
Q3 | $88.3M | Buy |
458,151
+131,345
| +40% | +$23.4M | 1.17% | 11 |
|
|
2018
Q2 | $55.5M | Buy |
326,806
+23,333
| +8% | +$3.62M | 0.88% | 16 |
|
|
2018
Q1 | $49.5M | Sell |
303,473
-52,302
| -15% | -$8.54M | 0.84% | 16 |
|
|
2017
Q4 | $53.3M | Sell |
355,775
-3,087
| -0.9% | -$457K | 0.92% | 13 |
|
|
2017
Q3 | $54.6M | Buy |
358,862
+85,442
| +31% | +$12.9M | 0.95% | 14 |
|
|
2017
Q2 | $35.2M | Buy |
273,420
+40,853
| +18% | +$4.92M | 0.66% | 25 |
|
|
2017
Q1 | $25.4M | Sell |
232,567
-24,851
| -10% | -$2.19M | 0.49% | 38 |
|
|
2016
Q4 | $19M | Buy |
257,418
+51,962
| +25% | +$4.23M | 0.44% | 53 |
|
|
2016
Q3 | $17.9M | Buy |
205,456
+59,226
| +41% | +$5.6M | 0.43% | 58 |
|
|
2016
Q2 | $12.6M | Sell |
146,230
-11,289
| -7% | -$975K | 0.33% | 78 |
|
|
2016
Q1 | $12.5M | Sell |
157,519
-85,643
| -35% | -$7.75M | 0.31% | 80 |
|
|
2015
Q4 | $30.6M | Sell |
243,162
-19,683
| -7% | -$2.38M | 0.82% | 23 |
|
|
2015
Q3 | $27.4M | Sell |
262,845
-1,009
| -0.4% | -$130K | 0.67% | 25 |
|
|
2015
Q2 | $32.6M | Buy |
263,854
+42,000
| +19% | +$5.29M | 0.68% | 26 |
|
|
2015
Q1 | $26.2M | Buy |
221,854
+20,332
| +10% | +$2.44M | 0.53% | 44 |
|
|
2014
Q4 | $23.9M | Buy |
+201,522
| New | +$22.7M | 0.5% | 55 |
|
Other funds holding VRTX
VCM
VPM
Candriam SCA's VRTX Position: Q1 2026 in Review
Candriam SCA increased its Vertex Pharmaceuticals (VRTX) stake by 1.6% in Q1 2026, buying an estimated $1.69M and bringing the position to 228,915 shares worth $102M. The position accounts for 0.53% of the portfolio, ranked #36.
Candriam SCA first reported a position in VRTX in Q4 2014 and has held it in 46 quarters since. The position peaked at $184M in Q4 2020. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Candriam SCA held 228,915 shares of Vertex Pharmaceuticals worth $102M as of Q1 2026.
- Candriam SCA bought 3,623 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.69M.
- Vertex Pharmaceuticals made up 0.53% of Candriam SCA's portfolio in Q1 2026, its #36 holding.
- Candriam SCA first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
- Candriam SCA's Vertex Pharmaceuticals position peaked at $184M in Q4 2020.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.